肾移植中低剂量西罗莫司对比吗替麦考酚酯联合缓释他克莫司的非劣效随机试验
多中心开放标签随机非劣效试验纳入158例肾移植受者,比较低剂量西罗莫司或吗替麦考酚酯联合缓释他克莫司及皮质激素。主要终点12个月内复合疗效失败率两组分别为6.6%和13.3%,绝对差6.8%(95%CI -2.8%至16.3%),低剂量西罗莫司方案非劣效且安全性相似。
要点
- 低剂量西罗莫司联合缓释他克莫司在肾移植中疗效不劣于吗替麦考酚酯方案。
- 12个月复合疗效失败率两组绝对差6.8%(95%CI -2.8%至16.3%)。
- 两组不良事件和严重不良事件发生率相似。
核心结论
- 低剂量西罗莫司联合缓释他克莫司在疗效和安全性方面不劣于吗替麦考酚酯联合缓释他克莫司。
研究设计与样本
- 多中心、开放标签、随机、对照、非劣效试验,随机分配158例肾移植患者接受低剂量西罗莫司或吗替麦考酚酯联合缓释他克莫司及皮质激素。
主要发现
- 意向治疗人群中,低剂量西罗莫司组12个月内复合疗效失败率为6.6%,吗替麦考酚酯组为13.3%,绝对差6.8%(95%CI -2.8%至16.3%)。
- 12个月内活检证实的急性排斥反应发生率低剂量西罗莫司组为5.3%,吗替麦考酚酯组为13.3%(P=0.09)。
- 移植后12个月平均估算肾小球滤过率低剂量西罗莫司组为53.2 mL/min/1.73 m2,吗替麦考酚酯组为52.4 mL/min/1.73 m2(P=0.76)。
- 两组不良事件和严重不良事件发生率相似。
关键数值与推荐
- 主要终点为移植后12个月内复合疗效失败率,包括活检证实的急性排斥反应、移植物丢失、死亡或失访。
临床怎么用
- 低剂量西罗莫司联合缓释他克莫司可作为肾移植免疫抑制方案,有效预防急性排斥反应并保护肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most of the previous studies reported that tacrolimus (TAC) with sirolimus (SRL) was associated with worse post-transplant outcomes in kidney transplantation, compared with TAC with mycophenolate mofetil (MMF). These might be attributable to high-dose SRL. However, outcomes using low-dose SRL with TAC for kidney transplantation are uncertain. The aim of this study was to assess the efficacy and safety of low-dose SRL with extended-release tacrolimus (ER-TAC) versus MMF with ER-TAC. METHODS: We randomly assigned 158 renal transplant patients to receive low-dose SRL or MMF in combination with ER-TAC and corticosteroid. The primary endpoint was the composite efficacy failure rate, including biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up, within 12 months post-transplantation. This trial is registered with ClinicalTrial.gov (number NCT01680952). RESULTS: The efficacy failure rate was 6.6% in the low-dose SRL group and 13.3% in the MMF group in the intention-to-treat population (absolute difference, 6.8%; 95% confidence interval, -2.8% to 16.3%). The incidence of BPAR within 12 months post-transplantation was 5.3% in the low-dose SRL group and 13.3% in the MMF group (P = 0.09). The mean estimated glomerular filtration rate at 12 months post-transplantation was 53.2 mL/min/1.73 m2 in the low-dose SRL group and 52.4 mL/min/1.73 m2 in the MMF group (P = 0.76). The incidences of adverse events and serious adverse events were similar between groups. CONCLUSION: Low-dose SRL with ER-TAC was not inferior to MMF with ER-TAC with respect to efficacy and safety. When used for immunosuppression in kidney transplantation, low-dose SRL with ER-TAC can effectively prevent acute rejection and preserve renal function.
引用
- Huh KH, Lee JG, Ha J, et al. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant. 2017. PMID: 28810721. doi:10.1093/ndt/gfx093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。